Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., a leading global player in the pharmaceutical industry, is headquartered in the United States. Founded in 1885, the company has established a strong presence in major operational regions, including Europe, Asia, and Latin America. Specialising in human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing, Boehringer Ingelheim is renowned for its innovative therapies and commitment to research and development. The company’s core products encompass a range of prescription medications, particularly in the fields of respiratory diseases, cardiovascular health, and oncology. Boehringer Ingelheim's unique approach to drug development and patient care has positioned it as a trusted name in the industry, with notable achievements in advancing treatment options and improving patient outcomes. With a focus on sustainability and social responsibility, Boehringer Ingelheim continues to make significant strides in enhancing global health.
DitchCarbon Score
How does Boehringer Ingelheim Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim Pharmaceuticals, Inc.'s score of 13 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Pharmaceuticals, Inc.'s reported carbon emissions
Boehringer Ingelheim Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available data on its carbon emissions, including specific figures for Scope 1, 2, or 3 emissions. Additionally, there are no documented reduction targets or climate pledges outlined in their sustainability initiatives. As a result, the company's current climate commitments and strategies remain unclear. In the context of the pharmaceutical industry, many companies are increasingly focusing on reducing their carbon footprints and setting ambitious targets to combat climate change. However, without specific data or commitments from Boehringer Ingelheim, it is difficult to assess their position in this critical area.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
